207 related articles for article (PubMed ID: 25047051)
61. Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia.
Madersbacher H; Stöhrer M; Richter R; Burgdörfer H; Hachen HJ; Mürtz G
Br J Urol; 1995 Apr; 75(4):452-6. PubMed ID: 7788255
[TBL] [Abstract][Full Text] [Related]
62. Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects.
Amend B; Hennenlotter J; Schäfer T; Horstmann M; Stenzl A; Sievert KD
Eur Urol; 2008 May; 53(5):1021-8. PubMed ID: 18243516
[TBL] [Abstract][Full Text] [Related]
63. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity.
Reitz A; Stöhrer M; Kramer G; Del Popolo G; Chartier-Kastler E; Pannek J; Burgdörfer H; Göcking K; Madersbacher H; Schumacher S; Richter R; von Tobel J; Schurch B
Eur Urol; 2004 Apr; 45(4):510-5. PubMed ID: 15041117
[TBL] [Abstract][Full Text] [Related]
64. Effect of trospium chloride therapy on intraocular pressure and tear secretion in overactive bladder patients.
Turkoglu AR; Parmak Yener N; Coban S; Guzelsoy M; Emul A; Demirbas M; Demirci H
Cutan Ocul Toxicol; 2017 Dec; 36(4):331-335. PubMed ID: 28468509
[TBL] [Abstract][Full Text] [Related]
65. Control of detrusor hyperreflexia by the intravesical instillation of oxybutynine hydrochloride.
Madersbacher H; Jilg G
Paraplegia; 1991 Feb; 29(2):84-90. PubMed ID: 2023781
[TBL] [Abstract][Full Text] [Related]
66. Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
Zát'ura F; Vsetica J; Abadías M; Pavlík I; Schraml P; Brod'ák M; Villoria J; Sust M;
Eur Urol; 2010 Jan; 57(1):145-52. PubMed ID: 19446951
[TBL] [Abstract][Full Text] [Related]
67. Detrusor botulinum toxin A injection significantly decreased urinary tract infection in patients with traumatic spinal cord injury.
Jia C; Liao LM; Chen G; Sui Y
Spinal Cord; 2013 Jun; 51(6):487-90. PubMed ID: 23357928
[TBL] [Abstract][Full Text] [Related]
68. Effects of Bilateral Transcutaneous Tibial Nerve Stimulation on Neurogenic Detrusor Overactivity in Spinal Cord Injury: A Urodynamic Study.
Kamboonlert K; Panyasriwanit S; Tantisiriwat N; Kitisomprayoonkul W
Arch Phys Med Rehabil; 2021 Jun; 102(6):1165-1169. PubMed ID: 33245938
[TBL] [Abstract][Full Text] [Related]
69. Oxybutynin in detrusor overactivity.
Diokno A; Ingber M
Urol Clin North Am; 2006 Nov; 33(4):439-45, vii. PubMed ID: 17011379
[TBL] [Abstract][Full Text] [Related]
70. Efficacy, tolerability, and safety of oxybutynin chloride in pediatric neurogenic bladder with spinal dysraphism: a retrospective, multicenter, observational study.
Lee JH; Kim KR; Lee YS; Han SW; Kim KS; Song SH; Baek M; Park K
Korean J Urol; 2014 Dec; 55(12):828-33. PubMed ID: 25512818
[TBL] [Abstract][Full Text] [Related]
71. Long-term urodynamic follow-up after external sphincterotomy in patients with spinal cord injury.
Takahashi R; Kimoto Y; Eto M
Neurourol Urodyn; 2018 Nov; 37(8):2625-2631. PubMed ID: 29717510
[TBL] [Abstract][Full Text] [Related]
72. Urodynamic parameters development and complications of clean intermittent self-catheterization in Chinese schoolchildren with neurogenic underactive bladder.
Wang QW; Song DK; Zhang XP; Wu YD; Zhang RL; Wei JX; Wen JG
Urol Int; 2011; 86(4):461-5. PubMed ID: 21555862
[TBL] [Abstract][Full Text] [Related]
73. Efficacy and safety of oxybutynin in children with detrusor hyperreflexia secondary to neurogenic bladder dysfunction.
Franco I; Horowitz M; Grady R; Adams RC; de Jong TP; Lindert K; Albrecht D
J Urol; 2005 Jan; 173(1):221-5. PubMed ID: 15592080
[TBL] [Abstract][Full Text] [Related]
74. Neurogenic detrusor overactivity treated with english botulinum toxin a: 8-year experience of one single centre.
Del Popolo G; Filocamo MT; Li Marzi V; Macchiarella A; Cecconi F; Lombardi G; Nicita G
Eur Urol; 2008 May; 53(5):1013-19. PubMed ID: 17950989
[TBL] [Abstract][Full Text] [Related]
75. [Efficacy of repeat injections of botulinum A toxin to the detrusor in neurogenic bladder overactivity].
Chenet A; Perrouin-Verbe B; Le Normand L; Labat JJ; Brunel P; Lefort M; Mathé JF
Ann Readapt Med Phys; 2007 Nov; 50(8):651-60. PubMed ID: 17490775
[TBL] [Abstract][Full Text] [Related]
76. Long-term response of different Botulinum toxins in refractory neurogenic detrusor overactivity due to spinal cord injury.
Lombardi G; Musco S; Bacci G; Celso M; Bellio V; Del Popolo G
Int Braz J Urol; 2017; 43(4):721-729. PubMed ID: 28537692
[TBL] [Abstract][Full Text] [Related]
77. Preoperative urodynamic factors predicting outcome of botulinum toxin-A intradetrusor injection in children with neurogenic detrusor overactivity.
Kim SW; Choi JH; Lee YS; Han SW; Im YJ
Urology; 2014 Dec; 84(6):1480-4. PubMed ID: 25432842
[TBL] [Abstract][Full Text] [Related]
78. Chapter 1: The conditions of neurogenic detrusor overactivity and overactive bladder.
Haab F
Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S2-5. PubMed ID: 25042138
[TBL] [Abstract][Full Text] [Related]
79. Detrusor overactivity in spina bifida: how long does it need to be treated?
Ab E; Dik P; Klijn AJ; van Gool JD; de Jong TP
Neurourol Urodyn; 2004; 23(7):685-8. PubMed ID: 15382196
[TBL] [Abstract][Full Text] [Related]
80. Patients' perspective of botulinum toxin-A as a long-term treatment option for neurogenic detrusor overactivity secondary to spinal cord injury.
Hori S; Patki P; Attar KH; Ismail S; Vasconcelos JC; Shah PJ
BJU Int; 2009 Jul; 104(2):216-20. PubMed ID: 19220255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
